Study of Diroximel Fumarate in the Real-World Setting
Public ClinicalTrials.gov record NCT04746976. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, Observational Study Evaluating Persistence on Treatment, Safety, Tolerability, and Effectiveness of Diroximel Fumarate in the Real-World Setting (EXPERIENCE-US Study)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to characterize the persistence to therapy in participants with relapsing forms of multiple sclerosis (RMS) treated with diroximel fumarate (DRF) in routine clinical practice. The secondary objectives of the study are to assess short-term persistence to treatment; to assess long-term persistence on treatment; to assess the effect of DRF on relapses; to assess the impact of DRF on cognition; to assess the impact of DRF on participant reported outcomes (PROs) and to explore the real-world safety profile of DRF (ie, gastrointestinal \[GI\] tolerability, lymphocyte dynamics, adverse events \[AEs\] leading to discontinuation, and serious adverse events \[SAEs\]).
Study identification
- NCT ID
- NCT04746976
- Recruitment status
- Terminated
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 75 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 1, 2021 (Actual)
- Primary completion
- Apr 14, 2023 (Actual)
- Completion
- Apr 14, 2023 (Actual)
- Last update posted
- May 26, 2023
2021 – 2023
United States locations
- U.S. sites
- 18
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Regina Berkovich MD Phd Inc | West Hollywood | California | 90048 | — |
| MedStar Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | — |
| Norton Neuroscience Institute | Louisville | Kentucky | 40207 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Glendale Neurological Associates, PC | Farmington | Michigan | 48071 | — |
| Memorial Healthcare | Owosso | Michigan | 48867 | — |
| St. Luke's Neurology | Kansas City | Missouri | 64111 | — |
| CentraState Healthcare System - Linda Cardinale MS Center | Freehold | New Jersey | 07728 | — |
| MS Center at St Barnabas | Livingston | New Jersey | 07039 | — |
| Multiple Sclerosis Center JSUMC | Neptune City | New Jersey | 07753 | — |
| Jacobs School of Medicine and Biomedical Sciences | Buffalo | New York | 14202 | — |
| Cone Health | Greensboro | North Carolina | 27405 | — |
| Providence Brain and Spine Institute | Portland | Oregon | 97225 | — |
| Geisinger Medical Center | Danville | Pennsylvania | 17822 | — |
| Hope Neurology | Knoxville | Tennessee | 37922 | — |
| UTHealth Neurosciences Texas Medical Center II | Houston | Texas | 77030 | — |
| Riverside Neurology Specialists | Newport News | Virginia | 23601 | — |
| Providence Medical Research Center | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04746976, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 26, 2023 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04746976 live on ClinicalTrials.gov.